Celltrion Inc
KRX:068270

Watchlist Manager
Celltrion Inc Logo
Celltrion Inc
KRX:068270
Watchlist
Price: 173 500 KRW -0.12% Market Closed
Market Cap: 36T KRW
Have any thoughts about
Celltrion Inc?
Write Note

Celltrion Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Celltrion Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Celltrion Inc
KRX:068270
Pre-Tax Income
â‚©397B
CAGR 3-Years
-19%
CAGR 5-Years
7%
CAGR 10-Years
10%
SK Bioscience Co Ltd
KRX:302440
Pre-Tax Income
â‚©7.3B
CAGR 3-Years
-42%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Pre-Tax Income
-â‚©26.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Pre-Tax Income
â‚©154.4B
CAGR 3-Years
18%
CAGR 5-Years
16%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Pre-Tax Income
â‚©115.8B
CAGR 3-Years
33%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Pre-Tax Income
-â‚©3.6B
CAGR 3-Years
34%
CAGR 5-Years
15%
CAGR 10-Years
N/A
No Stocks Found

Celltrion Inc
Glance View

Market Cap
36T KRW
Industry
Biotechnology

Celltrion Inc. is a South Korean biopharmaceutical company that has made significant strides in the development and commercialization of biosimilars, monoclonal antibodies, and novel therapeutics. Established in 2002, the company has positioned itself as a key player in the global pharmaceutical landscape, particularly known for its commitment to making biological drugs more accessible and affordable. With a robust pipeline of products targeting conditions such as autoimmune diseases, cancer, and infectious diseases, Celltrion leverages state-of-the-art biotechnology and a strong emphasis on research and development. This focus not only enhances its product offerings but also champions the company’s mission of improving patient outcomes worldwide. As the global market for biosimilars continues to expand, driven by increasing healthcare costs and an aging population, Celltrion stands at the forefront, equipped with a solid operational framework and a strategic partnership approach. The company’s flagship products, like Remsima, a biosimilar to Remicade, have achieved notable success, gaining approval in numerous countries and establishing a strong revenue stream. With its plans to diversify its product portfolio, including innovative therapies in oncology, Celltrion is poised for growth. For investors, this translates into a promising opportunity to tap into a company that not only prioritizes innovation but also operates within a rapidly evolving market characterized by increasing demand for more affordable biologics.

Intrinsic Value
187 892.7 KRW
Undervaluation 8%
Intrinsic Value
Price

See Also

What is Celltrion Inc's Pre-Tax Income?
Pre-Tax Income
397B KRW

Based on the financial report for Jun 30, 2024, Celltrion Inc's Pre-Tax Income amounts to 397B KRW.

What is Celltrion Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
10%

Over the last year, the Pre-Tax Income growth was -40%. The average annual Pre-Tax Income growth rates for Celltrion Inc have been -19% over the past three years , 7% over the past five years , and 10% over the past ten years .

Back to Top